Back to today’s briefing

Story perspectives

Scottish Medicines Rejects Alzheimer’s Drug, Approves Cancer Treatments

2/11/2025

31 7

Summary

Story summary

In a significant blow to Alzheimer’s patients, the Scottish Medicines Consortium has turned down lecanemab, deeming it too costly and uncertain in its effectiveness. This mirrors a previous rejection by NICE in England and Wales. On a brighter note, NHS Scotland has welcomed six new cancer treatments, including a promising option for advanced breast cancer.

1 of 1

Story summary

In a significant blow to Alzheimer’s patients, the Scottish Medicines Consortium has turned down lecanemab, deeming it too costly and uncertain in its effectiveness. This mirrors a previous rejection by NICE in England and Wales. On a brighter note, NHS Scotland has welcomed six new cancer treatments, including a promising option for advanced breast cancer.